U.S. stocks were on pace to close out their best week in nearly two years on Friday, helped by earnings from Microsoft and Procter & Gamble and as concerns eased over the possible spread of Ebola.

The S&P 500 is up 3.7 percent for the week, putting the index on track for its best week since the start of 2013, boosted by solid corporate earnings reports.

IsoRay, Inc.(NYSEMKT:ISR) is up on huge volume without any news. The stock made a similar move on October 7 but couldn't hold the gain. Shares reversed off the high of $2.12 all the way down to $1.22 on October 16.

IDEXX Laboratories, Inc.(NASDAQ:IDXX) Q3 results: Revenues: $383.5M (+13.4%); COGS: $170.2M (+11.6%); R&D Expense: $24.8M (+14.8%); SG&A: $116.3M (+17.8%); Operating Income: $72.2M (+10.2%); Net Income: $52.2M (+14.2%); EPS: $1.03 (+19.8%); Quick Assets: $292.7M (+4.9%).

Shire plc (NASDAQ:SHPG) Q3 results ($M): Revenues: 1,597.1 (+31.7%); COGS: 254.3 (+40.9%); R&D Expense: 228.6 (+1.1%); SG&A Expense: 522.9 (+31.9%); Operating Income: 572.0 (+49.4%); Net Income: 479.7 (+72.4%); Earnings/ADS: 2.427 (+65.8%); Quick Assets: 467.7 (-79.1%); CF Ops: 593.4 (+36.8%).

IGI Laboratories, Inc.(NYSEMKT:IG) Q3 results: Revenues: $6.7M (+67.5%); COGS: $4M (+48.1%); R&D Expense: $1.7M (+142.9%); SG&A: $1.1M (+57.1%); Operating Loss: ($0.14M) (-250.0%); Net Loss: ($0.2M) (-100.0%); EPS: $0.0 (unch); Quick Assets: $23.2M (+999%); CF Ops: ($1.0M) (+28.6%).

Recent IPO Vitae Pharmaceuticals (NASDAQ:VTAE) is up 33% on higher-than-normal volume in response to its announcement of results from a Phase 1 trial of its BACE inhibitor, VTP-37948, in Alzheimer's patients. The drug candidate appeared safe and tolerable. Partner Boehringer Ingelheim expects to initiate more Phase 1 studies to clarify the pharmacokinetic profile and ascending dose characteristics.